You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Multi-Functional Nanotube-Based Sensor Array for Detecting Blood Coagulation Defects

    SBC: INNOSENSE CORPORATION            Topic: DHA19A001

    Defense Health Agency (DHA) is seeking a multi-functional diagnostic to determine blood coagulopathy in real time at point-of-care (POC). Blood coagulopathy, resulting in uncontrolled bleeding, is implicated in 80% of operating room deaths and 50% of trau

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  2. Multipurpose reversible terminators

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: NHGRI

    DESCRIPTION (provided by applicant): This Phase 2 STTR application will allow the Foundation for Applied Molecular Evolution (FfAME) to complete its transfer of technology to Firebird Biomolecular Sciences LLC, allowing Firebird to commercialize nucleoside triphosphates where the 3'-OH groups are blocked by a 3'-ONH2 group. Triphosphates having this modification are accepted by DNA polymerases and ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Nanoliter electron paramagnetic resonance sensor based on diamond nanophotonics: a new tool for biomarker monitoring

    SBC: ODMR Technologies, Inc            Topic: 400

    DESCRIPTION provided by applicant ODMR Technologies Inc together with Victor Acostaandapos s group at University of New Mexico is developing a nanophotonic platform capable of uniquely detecting minute quantities of biomolecules The specific detection of biomolecules plays a central role in modern life science including cell systems biology high throughput drug scre ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases

    SBC: Nami Therapeutics Corp.            Topic: 102

    PROJECT SUMMARY ABSTRACT Ovarian cancer is the second most common gynecologic cancer in the United States and the most common cause of death among women with gynecologic malignanciesDespite advances in treatment strategiesperitoneal metastasis remains the primary cause of morbidity and mortality in ovarian cancerThe National Cancer Research Institute Clinical and Translational Radiotherapy Researc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Neuroprotective and Antiviral Effects of BMD-101 and BMD-104 in HIV Infection

    SBC: BIOMEDISYN CORPORATION            Topic: NIMH

    DESCRIPTION (provided by applicant): The introduction and implementation of highly active antiretroviral therapy (HAART) in AIDS patients diminished HIV viral load and led to an increase in life expectancy, but HIV infection can still lead to severe complications in the nervous system such as HIV-associated neurocognitive disorders (HAND) and sensory distal neuropathy (HIV-SN). For this patient po ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Neuroprotective therapy of stroke with HUCNC and simvastatin

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Nogo Decoy Receptor Therapy for the Treatment of Glaucoma

    SBC: RENETX BIO, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): The objective of this phase I STTR application is to continue assessment of the relevance and feasibility of Nogo decoy receptor therapy for the treatment of glaucoma. The secondary objective is to obtain pharmacokinetic data important for designing additional preclinical efficacy studies and formulating a drug development plan for glaucoma. Our long term objec ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Novel indication for myeloid progenitor use: Induction of tolerance

    SBC: Cellerant Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): State of the art techniques result in 10-year solid organ graft loss of up to 80% in cardiopulmonary organ transplantation, and re-transplantation is often not possible. Establishment of donor-specific immunological tolerance (DSIT), a condition in which a recipient accepts a transplant without immunosuppression, while retaining the ability to fight infections, ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Novel monoclonal antibody for single dose treatment of acute CNS injury

    SBC: Oncosynergy, Inc.            Topic: 999

    PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government